In other recent news, Walgreens Boots Alliance shareholders have overwhelmingly approved the company's acquisition by Sycamore Partners, with approximately 96% of votes cast in favor of the deal. This transaction will see shareholders receive $11.45 per share in cash, with a potential additional $3.00 per share from future monetization of Walgreens' interests in VillageMD. In a separate development, Walgreens has terminated two major credit agreements and launched a new $2.5 billion accounts receivable facility to repay existing debts. Meanwhile, Walgreens has reached a $300 million settlement with the Department of Justice over allegations related to opioid dispensing, which concludes a series of litigations involving the company. Evercore ISI has maintained its In Line rating on Walgreens stock, with a price target of $11.45, aligning with the acquisition price from Sycamore Partners.